Stage III Melanoma Clinical Trial
Official title:
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Adjuvant Melanoma Setting
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
Cancer cells harbor and can acquire potentially hundreds of mutations, many of whom are found in the ctDNA. Circulating tumor DNA (ctDNA) holds the promise for the 50% of participants who do not need adjuvant therapies - participants could be monitored to ensure no increase in ctDNA. Participants treated could then be followed for the earliest possible blood level signs of recurrence (incr. ctDNA) and more quickly be switched to more effective therapies. Further, the treating physician could hold therapy until the first signs of ctDNA based recurrence for those participants that would benefit. Blood sample from a biobank will be used to identify to monitor ctDNA. These blood samples were drawn at baseline, 3 months, 6 months and 18 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03200847 -
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT01875653 -
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
|
Phase 3 | |
| Terminated |
NCT01026051 -
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
|
Phase 2 | |
| Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT02794636 -
Interferon Toxicities in Melanoma Treatment
|
N/A | |
| Terminated |
NCT00082875 -
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00003789 -
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
|
Phase 3 | |
| Active, not recruiting |
NCT03719131 -
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
|
Phase 2 | |
| Completed |
NCT01376713 -
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT00450255 -
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00119249 -
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
|
Phase 2 | |
| Terminated |
NCT00087386 -
Tanespimycin in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT03385486 -
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
|
Phase 1 | |
| Completed |
NCT02073123 -
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01168050 -
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
|
Phase 2 | |
| Terminated |
NCT00945269 -
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00217542 -
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Completed |
NCT00089362 -
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
| Completed |
NCT00003647 -
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 3 | |
| Completed |
NCT04059224 -
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
|
Phase 2 |